Aurinia Pharmaceuticals Q4 Earnings Call Highlights

For the full year ended Dec. 31, 2025, Aurinia reported total revenue of $283.1 million, up 20% from $235.1 million in 2024. Miller noted that 2024 revenue included a one-time $10 million milestone payment tied to LUPKYNIS regulatory approval in Japan; excluding that milestone, Aurinia said total revenue increased 26% year over year. Full-year net product sales of LUPKYNIS were $271.3 million, up 25% from $216.2 million in 2024.Aurinia posted net income of $210.8 million for the fourth quarter, compared wit ...